Apremilast |
eMediNexus Coverage from: 
Dr KN Sarveswari, Chennai,  21 January 2019
Coronavirus Live Count Map India

remove_red_eye 673 Views
COVID-19 Vaccine Updates

Coronavirus Protocols


0 Read Comments                

Orally administered apremilast is an effective generally well-tolerated and convenient option for the treatment of many chronic inflammatory dermatoses. It does not cause immune suppression but acts by targeting the central inflammatory signalling pathways.Hence, it has an added advantage over conventional treatment modalities available. It is not associated with an increased risk of infection or malignancy and no lab monitoring is required.However, a low drug survival beyond 6-8 months as repor...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now